Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
An Executive Order signed by President Donald J. Trump on April 18, 2026, will significantly advance psychedelic therapy access for serious mental illness. By removing regulatory and scheduling barriers, the order directs the FDA to issue Commissioner’s National Priority Vouchers for eligible psychedelic drugs with Breakthrough Therapy designation, creates a Right to Try–style pathway for investigational agents such as ibogaine, and requires immediate rescheduling reviews upon successful Phase 3 completion.
Breaking Down Scheduling Barriers
The Order’s most impactful elements address long-standing Schedule I restrictions that have historically limited clinical development of psychedelics. By requiring the Attorney General to initiate rescheduling reviews immediately after successful Phase 3 trials, the policy shortens the lag between efficacy demonstration and potential rescheduling. This directly improves psychedelic therapy access timelines for treatment-resistant populations.
The allocation of $50 million in ARPA-H matching funds builds on the 2025 Texas ibogaine research consortium. It aims to stimulate additional state investment and create a multiplier effect on evidence generation for these promising therapies.
Right to Try Expansion for Psychedelics
The expanded Right to Try pathway—originally enacted during the first Trump Administration—now explicitly includes investigational psychedelics that meet basic safety criteria. Combined with prioritized FDA review via Commissioner’s National Priority Vouchers, these mechanisms target the millions of U.S. adults experiencing substantial functional impairment despite existing treatments.
The order operationalizes two key precedents: the Right to Try Act and the HALT Fentanyl Act of 2025. It directs the FDA, DEA, HHS, and VA to collaborate on expanding access and boosting veteran participation in clinical trials. The policy draws on ongoing research at Stanford, Harvard, and Johns Hopkins, as well as the Texas state consortium launched in 2025.
HEOR and Market Access Implications
From a Health Economics and Outcomes Research perspective, the Order should compress evidence-generation timelines and reduce late-stage development costs. Faster rescheduling upon Phase 3 success and expanded patient access through the Right to Try mechanism are expected to improve trial recruitment and generate real-world evidence earlier.
For market access and reimbursement, these changes could shorten time-to-launch, ease the economic burden of prolonged disability and suicide-related costs, and support more rapid coverage decisions by payers once robust outcomes data are available. The $50 million ARPA-H matching provision may also encourage public–private partnerships that help distribute development risk.
